JP7090335B2 - 治療剤に対する免疫応答を除去するための改善された方法及び化合物 - Google Patents

治療剤に対する免疫応答を除去するための改善された方法及び化合物 Download PDF

Info

Publication number
JP7090335B2
JP7090335B2 JP2018515566A JP2018515566A JP7090335B2 JP 7090335 B2 JP7090335 B2 JP 7090335B2 JP 2018515566 A JP2018515566 A JP 2018515566A JP 2018515566 A JP2018515566 A JP 2018515566A JP 7090335 B2 JP7090335 B2 JP 7090335B2
Authority
JP
Japan
Prior art keywords
sequence
epitope
protein
seq
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018515566A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528237A (ja
JP2018528237A5 (enExample
Inventor
サン－レミ，ジャン－マリー
ヴァンデルエルスト，リュック
カルリエ，ヴァンサン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imcyse SA
Original Assignee
Imcyse SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imcyse SA filed Critical Imcyse SA
Publication of JP2018528237A publication Critical patent/JP2018528237A/ja
Publication of JP2018528237A5 publication Critical patent/JP2018528237A5/ja
Application granted granted Critical
Publication of JP7090335B2 publication Critical patent/JP7090335B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018515566A 2015-09-25 2016-09-23 治療剤に対する免疫応答を除去するための改善された方法及び化合物 Active JP7090335B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15186845 2015-09-25
EP15186845.2 2015-09-25
PCT/EP2016/072690 WO2017050966A1 (en) 2015-09-25 2016-09-23 Improved methods and compounds for eliminating immune responses to therapeutic agents

Publications (3)

Publication Number Publication Date
JP2018528237A JP2018528237A (ja) 2018-09-27
JP2018528237A5 JP2018528237A5 (enExample) 2019-11-07
JP7090335B2 true JP7090335B2 (ja) 2022-06-24

Family

ID=54251983

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018515566A Active JP7090335B2 (ja) 2015-09-25 2016-09-23 治療剤に対する免疫応答を除去するための改善された方法及び化合物

Country Status (8)

Country Link
US (2) US11787849B2 (enExample)
EP (2) EP3352782B1 (enExample)
JP (1) JP7090335B2 (enExample)
CN (1) CN108289941B (enExample)
AU (2) AU2016328582B2 (enExample)
CA (1) CA2995771A1 (enExample)
ES (1) ES2874077T3 (enExample)
WO (1) WO2017050966A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2657480T3 (es) 2006-08-11 2018-03-05 Life Sciences Research Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
EP2623115A1 (en) 2008-02-14 2013-08-07 Life Sciences Research Partners VZW Immunogenic control of tumours and tumour cells
EP2719396B1 (en) 2008-02-14 2017-06-21 Life Sciences Research Partners VZW Immunotherapy targeting intracellular pathogens
JP6173915B2 (ja) 2010-11-25 2017-08-02 イムナテ・ソシエテ・ア・レスポンサビリテ・リミテＩｍｎａｔｅ Ｓａｒｌ 感染症、自己免疫疾患、同種因子に対する免疫応答、アレルギー性疾患、腫瘍、移植片拒絶反応、および、遺伝子療法または遺伝子ワクチン接種のために使用されるウイルスベクターに対する免疫応答の予防および／または治療における使用のための免疫原性ペプチド
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
EP3352782B1 (en) 2015-09-25 2021-03-31 ImCyse SA Improved methods and compounds for eliminating immune responses to therapeutic agents
KR20180134935A (ko) 2016-04-19 2018-12-19 임시스 에스에이 신규 면역원성 CD1d 결합 펩티드
WO2020229703A1 (en) * 2019-05-16 2020-11-19 Imcyse Sa Immunogenic peptides with an oxidoreductase motif comprising a modified cysteine
CA3182111A1 (en) * 2020-05-06 2021-11-11 Imcyse Sa Immunogenic peptides with extended oxidoreductase motifs
JP2023525080A (ja) * 2020-05-06 2023-06-14 アンシス・エスア 新たな酸化還元酵素モチーフを有する免疫原性ペプチド
CU20220066A7 (es) * 2020-05-06 2023-06-13 Imcyse Sa Péptidos inmunogénicos útiles en el tratamiento de esclerosis múltiple
CN113621030B (zh) * 2020-07-14 2023-05-26 上海科技大学 一种诱导蛋白质降解的多肽及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070184023A1 (en) 2003-10-30 2007-08-09 Pharmexa A/S Method for down-regulation of vegf
WO2009101204A3 (en) 2008-02-14 2009-10-08 Life Sciences Research Partners Vzw Elimination of immune responses to viral vectors
JP2010500308A (ja) 2006-08-11 2010-01-07 ライフ・サイエンシーズ・リサーチ・パートナーズ・フェレニゲング・ゾンデル・ウィンストーメルク 免疫原性ペプチドおよび免疫障害におけるその使用
WO2009101206A3 (en) 2008-02-14 2011-02-17 Life Sciences Research Partners Vzw Strategies to prevent and/or treat immune responses to soluble allofactors
JP2014501508A (ja) 2010-11-25 2014-01-23 イムナテ・ソシエテ・ア・レスポンサビリテ・リミテ 感染症、自己免疫疾患、同種因子に対する免疫応答、アレルギー性疾患、腫瘍、移植片拒絶反応、および、遺伝子療法または遺伝子ワクチン接種のために使用されるウイルスベクターに対する免疫応答の予防および／または治療における使用のための免疫原性ペプチド

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU579148B2 (en) 1984-03-09 1988-11-17 Scripps Clinic And Research Foundation Synthetic hepatitis b virus vaccine including both t cell and b cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4886782A (en) 1987-02-26 1989-12-12 The United States Of America As Represented By The Department Of Health And Human Services Malarial immunogen
US5433948A (en) 1990-02-13 1995-07-18 Thomas; Wayne R. Cloning and sequencing of allergens of dermatophagoides (house dust mite)
ATE238065T1 (de) 1990-09-27 2003-05-15 Tripep Ab Peptide zur verwendung in impfung und anregung von antikörperbildung gegen menschliches immunschwäche virus
EP0623168B1 (en) 1991-10-16 2009-09-30 Merck Patent GmbH T cell epitopes of the major allergens from dermatophagoides (house dust mite)
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US5589582A (en) 1992-10-27 1996-12-31 Biotransplant, Inc. Polynucleotides en coding porcine cytokines
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
US5824315A (en) 1993-10-25 1998-10-20 Anergen, Inc. Binding affinity of antigenic peptides for MHC molecules
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
AU1124499A (en) 1997-10-28 1999-05-17 Maxygen, Inc. Human papillomavirus vectors
NO315238B1 (no) 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
US20030152581A1 (en) 1998-07-30 2003-08-14 Jean-Marie Saint-Remy Compound and method for the prevention and/or the treatment of allergy
AR020102A1 (es) 1998-07-30 2002-04-10 Ucb Sa Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento
AU2150900A (en) 1998-11-16 2000-06-05 Board Of Regents, The University Of Texas System Hiv-specific t-cell induction
GB0006437D0 (en) 2000-03-17 2000-05-10 Leuven Res & Dev Vzw Compounds for the modulation of allergen sensitivity by antigens sharing T cell epitopes with allergens
WO2001083761A1 (en) * 2000-04-28 2001-11-08 Novozymes A/S Laccase mutants
US20030104570A1 (en) 2000-06-26 2003-06-05 Cabezon Silva Teresa Elisa Virginia Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
WO2002097070A1 (en) 2001-05-30 2002-12-05 Fondazione Telethon Ex-vivo isolated cd25+cd4+ t cells with immunosuppressive activity and uses thereof
WO2003031477A1 (en) 2001-10-03 2003-04-17 Unilever N.V. Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents, and compositions containing them
WO2003072731A2 (en) 2002-02-21 2003-09-04 Apovia, Inc. STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS
US20100183652A1 (en) 2002-02-21 2010-07-22 Mark Page STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS
JP4406607B2 (ja) 2002-08-26 2010-02-03 オンコセラピー・サイエンス株式会社 ペプチド及びこれを含む医薬
SI1548032T1 (sl) 2002-09-12 2009-10-31 Oncotherapy Science Inc KDR peptidi in cepiva, ki obsegajo le-te
JP2004147649A (ja) 2002-10-11 2004-05-27 Kumamoto Technology & Industry Foundation 頭頚部癌の抗原
EP1609107A4 (en) 2003-03-28 2006-08-30 Idm Pharma Inc METHOD FOR IDENTIFYING OPTIMAL PEPTIDE PITOPARIANTS
US7651855B2 (en) 2003-04-17 2010-01-26 The Trustees Of The University Of Pennsylvania Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses
GB0324265D0 (en) 2003-10-16 2003-11-19 Medical Res Council Peptide
JP2008044848A (ja) 2004-11-30 2008-02-28 Univ Kurume Ｈｌａ−ａ２４拘束性腫瘍抗原ペプチド
US8252893B2 (en) 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
GB0603081D0 (en) 2006-02-15 2006-03-29 Dynal Biotech Asa Oslo Method
FR2898275B1 (fr) 2006-03-10 2012-12-14 Genethon Cellules t regulatrices cd4+cd25+specifiques pour la greffe de cellules hematopoietiques et la tolerance immunitaire
WO2007135684A2 (en) 2006-05-22 2007-11-29 Hadasit Medical Research Services & Development Limited Method of treatment of anti-cd4 autoimmunity
EP2158211B1 (en) 2007-05-31 2016-08-10 Medigene AG Mutated structural protein of a parvovirus
CA2700618A1 (en) 2007-09-27 2009-04-02 The Board Of Trustees Of The University Of Arkansas Inhibition of dendritic cell-driven regulatory t cell activation and potentiation of tumor antigen-specific t cell responses by interleukin-15 and map kinase inhibitor
EP2719396B1 (en) 2008-02-14 2017-06-21 Life Sciences Research Partners VZW Immunotherapy targeting intracellular pathogens
EP2623115A1 (en) 2008-02-14 2013-08-07 Life Sciences Research Partners VZW Immunogenic control of tumours and tumour cells
AU2009214041A1 (en) 2008-02-14 2009-08-20 Katholieke Universiteit Leuven CD4+ T-cells with cytolytic properties
US9248171B2 (en) 2008-02-14 2016-02-02 Imcyse Sa Immunogenic peptides and their use in transplantation
EP2254592B1 (en) 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
KR101022649B1 (ko) 2008-08-07 2011-03-22 삼성모바일디스플레이주식회사 헤테로고리 화합물 및 이를 이용한 유기 전계 발광 장치
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
KR101866301B1 (ko) 2010-03-29 2018-06-11 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 하나 이상의 ｃｘｘｃ 모티프를 포함하는 폴리펩티드 및 이종 항원을 포함하는 약학 조성물 및 이의 용도
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
HK1202051A1 (en) 2012-02-15 2015-09-18 洛桑聚合联合学院 Erythrocyte-binding therapeutics
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201315946D0 (en) 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
GB201319160D0 (en) * 2013-10-30 2013-12-11 Imcyse Sa Methods for induction of antigen-specific regulatory t cells
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
EP3352782B1 (en) 2015-09-25 2021-03-31 ImCyse SA Improved methods and compounds for eliminating immune responses to therapeutic agents
KR20180134935A (ko) 2016-04-19 2018-12-19 임시스 에스에이 신규 면역원성 CD1d 결합 펩티드

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070184023A1 (en) 2003-10-30 2007-08-09 Pharmexa A/S Method for down-regulation of vegf
JP2010500308A (ja) 2006-08-11 2010-01-07 ライフ・サイエンシーズ・リサーチ・パートナーズ・フェレニゲング・ゾンデル・ウィンストーメルク 免疫原性ペプチドおよび免疫障害におけるその使用
WO2009101204A3 (en) 2008-02-14 2009-10-08 Life Sciences Research Partners Vzw Elimination of immune responses to viral vectors
WO2009101206A3 (en) 2008-02-14 2011-02-17 Life Sciences Research Partners Vzw Strategies to prevent and/or treat immune responses to soluble allofactors
JP2014501508A (ja) 2010-11-25 2014-01-23 イムナテ・ソシエテ・ア・レスポンサビリテ・リミテ 感染症、自己免疫疾患、同種因子に対する免疫応答、アレルギー性疾患、腫瘍、移植片拒絶反応、および、遺伝子療法または遺伝子ワクチン接種のために使用されるウイルスベクターに対する免疫応答の予防および／または治療における使用のための免疫原性ペプチド

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ELIN MALEK ABRAHIMIANS，MHC CLASS II-RESTRICTED EPITOPES CONTAINING AN OXIDOREDUCTASE ACTIVITY PROMPT CD4(+) 以下備考，FRONTIERS IN IMMUNOLOGY，2015年09月02日，VOL:6,，PAGE(S):449/1-5，http://dx.doi.org/10.3389/fimmu.2015.00449，T CELLS WITH APOPTOSIS-INDUCING PROPERTIES
VINCENT A CARLIER，INCREASED SYNAPSE FORMATION OBTAINED BY T CELL EPITOPES CONTAINING A CXXC MOTIF IN 以下備考，PLOS ONE，2012年01月01日，VOL:7, NR:10,，PAGE(S):E45366/1-16，http://dx.doi.org/10.1371/journal.pone.0045366，FLANKING RESIDUES CONVERT CD4+ T CELLS INTO CYTOLYTIC EFFECTORS

Also Published As

Publication number Publication date
EP3939606A3 (en) 2022-04-20
CN108289941B (zh) 2022-06-21
US20180258154A1 (en) 2018-09-13
WO2017050966A1 (en) 2017-03-30
US11787849B2 (en) 2023-10-17
JP2018528237A (ja) 2018-09-27
CN108289941A (zh) 2018-07-17
EP3939606A2 (en) 2022-01-19
AU2023201135A1 (en) 2023-03-30
AU2016328582A1 (en) 2018-03-15
EP3352782A1 (en) 2018-08-01
CA2995771A1 (en) 2017-03-30
HK1252695A1 (en) 2019-05-31
US20240109951A1 (en) 2024-04-04
EP3352782B1 (en) 2021-03-31
ES2874077T3 (es) 2021-11-04
AU2016328582B2 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
JP7090335B2 (ja) 治療剤に対する免疫応答を除去するための改善された方法及び化合物
JP2024045573A (ja) 腫瘍特異的なネオ抗原を同定する組成物および方法
JP2024012365A (ja) 新生抗原のためのジャンクションエピトープ提示の低減
KR102228843B1 (ko) Cd4+ t-세포 반응의 증강을 위한 변형된 에피토프
CN106573960B (zh) 用于针对乙型肝炎病毒感染的治疗性接种的合成长肽(slp)
RU2761653C2 (ru) Пептиды и способы для лечения диабета
JPH08504177A (ja) 免疫調節ペプチド
EA029831B1 (ru) Пептид, индуцирующий цитотоксические т-лимфоциты и стимулирующий антиопухолевые иммунные ответы
WO2003026691A2 (en) Use of hmgb1 for the activation of dendritic cells
AU2002341266A1 (en) Use of HMGB1 for the activation of dendritic cells
JP2022513019A (ja) 新規の酸化還元酵素モチーフを有する免疫原性ペプチド
JP2016527875A (ja) Ｃｄ４＋ｔリンパ球の検出、調製および枯渇のための向上した方法
JP2025158982A (ja) 糖尿病患者を階層化する方法
KR20240015672A (ko) 면역원성 펩티드를 사용한 개선된 치료 방법
HK40064028A (en) Improved methods and compounds for eliminating immune responses to therapeutic agents
JP5189593B2 (ja) 無差別ＨＥＲ−２／ＮｅｕＣＤ４Ｔ細胞エピトープ
HK1252695B (en) Improved methods and compounds for eliminating immune responses to therapeutic agents
CN108135973A (zh) 调节炎症应答及治疗不良心血管事件、病和粥样硬化的人apob100表位、方法和用途
JP2023538002A (ja) 制御性ｔ細胞エピトープ
JP2022542120A (ja) 抗原性ポリペプチドおよびその使用方法
HK40011939A (en) Human alpha fetoprotein-specific t cell receptors and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190924

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211008

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220112

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220517

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220607

R150 Certificate of patent or registration of utility model

Ref document number: 7090335

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150